(877) 320-5131 Menu
(877) 320-5131
Contact
Patient Portal

Recruiting

1280-0022 Xenera-1: A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab incombination with everolimus and exemestane versus everolimus andexemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease


A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (BYLieve)


Carrick Therapeutics: CT7001_002: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer:


G1 Therapeutics G1T48-01: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 inWomen with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer


Genentech: WO41554: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER:

Upcoming

DZ2019ER001 Study for Breast Cancer: A Phase I/II, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD3969 as Monotherapy or in combination with Palbociclib in Postmenopausal Female Patients with Estrogen Receptor Positive (ER+) and HER2 Negative (HER2-) Breast Cancer:

Astellas: An Open-Label, Multicenter, Multi-Cohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202):

Not Recruiting

A companion sample collection study to support the discovery of breast cancer aberrations with treatment of CDK4/6 therapy/LEE011/Ribociclib


COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease


Madeline: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer


monarchE: Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer


POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study


SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment


SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

Schedule a Consultation

Your health is important, and we welcome the opportunity to help you heal.


To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or Click the link below to access our Online Appointment Request

Book An Appointment

© Beverly Hills Cancer Center. All Rights Reserved. Web Design & Internet Marketing by Studio III

Privacy Policy

Rate Us
Rate us on Google Rate us on Yelp Rate us on HealthGrades Rate us on Facebook Rate us on Yahoo! Rate us on WebMD
Contact Us